Equine Encephalitis - Pipeline Review, H2 2016

Global Markets Direct’s, ‘Equine Encephalitis - Pipeline Review, H2 2016’, provides an overview of the Equine Encephalitis pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Equine Encephalitis, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Equine Encephalitis and features dormant and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

The report provides a snapshot of the global therapeutic landscape of Equine Encephalitis

The report reviews pipeline therapeutics for Equine Encephalitis by companies and universities/research institutes based on information derived from company and industry-specific sources

The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

The report reviews key players involved Equine Encephalitis therapeutics and enlists all their major and minor projects

The report assesses Equine Encephalitis therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type

The report summarizes all the dormant and discontinued pipeline projects

The report reviews latest news related to pipeline therapeutics for Equine Encephalitis

Reasons to buy

Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

Identify and understand important and diverse types of therapeutics under development for Equine Encephalitis

Identify potential new clients or partners in the target demographic

Develop strategic initiatives by understanding the focus areas of leading companies

Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics

Devise corrective measures for pipeline projects by understanding Equine Encephalitis pipeline depth and focus of Indication therapeutics

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Companies mentioned

Akshaya Bio Inc.

Altravax, Inc.

EpiVax, Inc.

Integrated BioTherapeutics, Inc.

Karyopharm Therapeutics, Inc.

Profectus BioSciences, Inc.

Akshaya Bio Inc.

Altravax, Inc.

EpiVax, Inc.

Integrated BioTherapeutics, Inc.

Karyopharm Therapeutics, Inc.

Profectus BioSciences, Inc.

Table of Contents

Table of Contents

Table of Contents 2

List of Tables 4

List of Figures 5

Introduction 6

Global Markets Direct Report Coverage 6

Equine Encephalitis ...

Table of Contents

Table of Contents 2

List of Tables 4

List of Figures 5

Introduction 6

Global Markets Direct Report Coverage 6

Equine Encephalitis Overview 7

Therapeutics Development 8

Pipeline Products for Equine Encephalitis - Overview 8

Pipeline Products for Equine Encephalitis - Comparative Analysis 9

Equine Encephalitis - Therapeutics under Development by Companies 10

Equine Encephalitis - Therapeutics under Investigation by Universities/Institutes 11

Equine Encephalitis - Pipeline Products Glance 12

Clinical Stage Products 12

Early Stage Products 13

Equine Encephalitis - Products under Development by Companies 14

Equine Encephalitis - Products under Investigation by Universities/Institutes 15

Equine Encephalitis - Companies Involved in Therapeutics Development 16

Akshaya Bio Inc. 16

Altravax, Inc. 17

EpiVax, Inc. 18

Integrated BioTherapeutics, Inc. 19

Karyopharm Therapeutics, Inc. 20

Profectus BioSciences, Inc. 21

Equine Encephalitis - Therapeutics Assessment 22

Assessment by Monotherapy Products 22

Assessment by Target 23

Assessment by Mechanism of Action 25

Assessment by Route of Administration 27

Assessment by Molecule Type 29

Drug Profiles 31

DEF-201 - Drug Profile 31

Product Description 31

Mechanism Of Action 31

R&D Progress 31

equine encephalitis vaccine - Drug Profile 33

Product Description 33

Mechanism Of Action 33

R&D Progress 33

equine encephalitis vaccine - Drug Profile 34

Product Description 34

Mechanism Of Action 34

R&D Progress 34

equine encephalitis vaccine - Drug Profile 35

Product Description 35

Mechanism Of Action 35

R&D Progress 35

imatinib mesylate - Drug Profile 36

Product Description 36

Mechanism Of Action 36

R&D Progress 36

Monoclonal Antibodies for Equine Encephalitis and Chikungunya - Drug Profile 37

Product Description 37

Mechanism Of Action 37

R&D Progress 37

Monoclonal Antibody for Venezuelan Equine Encephalitis - Drug Profile 38

Product Description 38

Mechanism Of Action 38

R&D Progress 38

nilotinib - Drug Profile 39

Product Description 39

Mechanism Of Action 39

R&D Progress 39

TSI-GSD-104 - Drug Profile 40

Product Description 40

Mechanism Of Action 40

R&D Progress 40

Vaccine for Western Equine Encephalitis - Drug Profile 41

Product Description 41

Mechanism Of Action 41

R&D Progress 41

venezuelan equine encephalitis vaccine - Drug Profile 42

Product Description 42

Mechanism Of Action 42

R&D Progress 42

Venezuelan equine encephalitis vaccine - Drug Profile 43

Product Description 43

Mechanism Of Action 43

R&D Progress 43

venezuelan equine encephalitis vaccine - Drug Profile 44

Product Description 44

Mechanism Of Action 44

R&D Progress 44

verdinexor - Drug Profile 45

Product Description 45

Mechanism Of Action 45

R&D Progress 45

Westrern Equine Encephalitis Virus Vaccine - Drug Profile 46

Product Description 46

Mechanism Of Action 46

R&D Progress 46

Equine Encephalitis - Dormant Projects 47

Equine Encephalitis - Product Development Milestones 48

Featured News & Press Releases 48

Dec 09, 2015: Profectus BioSciences Receives $4.6 Million DOD Grant to Develop Vaccine for Western, Eastern, and Venezuelan Equine Encephalitis Viruses 48

Dec 09, 2015: Profectus BioSciences Receives $4.6 Million DOD Grant to Develop Vaccine for Western, Eastern, and Venezuelan Equine Encephalitis Viruses 48

Appendix 50

Methodology 50

Coverage 50

Secondary Research 50

Primary Research 50

Expert Panel Validation 50

Contact Us 50

Disclaimer 51

List of Tables

List of Tables

Number of Products under Development for Equine Encephalitis, H2 2016 8

Number of Products under Development for Equine Encephalitis - Comparative Analysis, ...

List of Tables

Number of Products under Development for Equine Encephalitis, H2 2016 8

Number of Products under Development for Equine Encephalitis - Comparative Analysis, H2 2016 9

Number of Products under Development by Companies, H2 2016 10

Number of Products under Investigation by Universities/Institutes, H2 2016 11

Comparative Analysis by Clinical Stage Development, H2 2016 12

Comparative Analysis by Early Stage Development, H2 2016 13

Products under Development by Companies, H2 2016 14

Products under Investigation by Universities/Institutes, H2 2016 15

Equine Encephalitis - Pipeline by Akshaya Bio Inc., H2 2016 16

Equine Encephalitis - Pipeline by Altravax, Inc., H2 2016 17

Equine Encephalitis - Pipeline by EpiVax, Inc., H2 2016 18

Equine Encephalitis - Pipeline by Integrated BioTherapeutics, Inc., H2 2016 19

Equine Encephalitis - Pipeline by Karyopharm Therapeutics, Inc., H2 2016 20

Equine Encephalitis - Pipeline by Profectus BioSciences, Inc., H2 2016 21

Assessment by Monotherapy Products, H2 2016 22

Number of Products by Stage and Target, H2 2016 24

Number of Products by Stage and Mechanism of Action, H2 2016 26

Number of Products by Stage and Route of Administration, H2 2016 28

Number of Products by Stage and Molecule Type, H2 2016 30

Equine Encephalitis - Dormant Projects, H2 2016 47

List of Figures

List of Figures

Number of Products under Development for Equine Encephalitis, H2 2016 8

Number of Products under Development for Equine Encephalitis - Comparative Analysis, ...

List of Figures

Number of Products under Development for Equine Encephalitis, H2 2016 8

Number of Products under Development for Equine Encephalitis - Comparative Analysis, H2 2016 9

Number of Products under Development by Companies, H2 2016 10

Number of Products under Investigation by Universities/Institutes, H2 2016 11

Comparative Analysis by Clinical Stage Development, H2 2016 12

Comparative Analysis by Early Stage Products, H2 2016 13

Assessment by Monotherapy Products, H2 2016 22

Number of Products by Targets, H2 2016 23

Number of Products by Stage and Targets, H2 2016 23

Number of Products by Mechanism of Actions, H2 2016 25

Number of Products by Stage and Mechanism of Actions, H2 2016 25

Number of Products by Routes of Administration, H2 2016 27

Number of Products by Stage and Routes of Administration, H2 2016 27

Number of Products by Molecule Types, H2 2016 29

Number of Products by Stage and Molecule Types, H2 2016 29

    Pricing

Discounts available for multiple report purchases.

reportstore@globalmarketsdirect.com
+44 (0) 161 359 5414

Saved reports